Descripción del proyecto
Una tecnología novedosa para desarrollar probióticos personalizados
Los trastornos del microbioma intestinal están relacionados con muchas enfermedades diferentes como, por ejemplo, la diabetes, la obesidad y el cáncer. A pesar de la importancia que tiene el microbioma para la salud, los probióticos disponibles no proporcionan una cantidad y una variedad suficientes de bacterias para colonizar el intestino. Para resolver este problema, el proyecto financiado con fondos europeos MBSelect empleará una tecnología desarrollada recientemente que permite cultivar comunidades bacterianas complejas en micropartículas y, seguidamente, encapsularlas tras liofilizarlas. Esta tecnología favorece, por primera vez, el desarrollo de probióticos personalizados a partir de microbiomas, adaptados a cualquier finalidad, edad o sexo. El proyecto ampliará está tecnología innovadora a nivel industrial y llevará a cabo las actividades necesarias para su comercialización.
Objetivo
Gut-microbiome is an essential part of human health. Gut bacteria imbalance is now recognized as a crucial factor in the development of many diseases – chronic, obesity, diabetes, liver, cardio, cancer and neurodegenerative. Traditional probiotics used today, aimed at restoring this imbalance, are not effective: They are incapable of delivering sufficient number and variety of bacteria to the correct location in the gut and have them colonize. MyBiotics, a microbiome company, developed a novel technology for very efficient growth, delivery, and colonization of needed bacteria types in the gut. The technology uses innovative fermentation methods to grow complex bacteria communities on micro-particles, dry it to powder and place into capsules administered like any probiotic supplement. MyBiotics proved the technology for single-strain-bacteria and for replicating multi-strain biological samples. In this project it is introducing MBSelect, which will remove the reliance on a biological sample and add formulation of multi-strain communities of human bacteria, grown in pre-selected clusters in any combination. The MBSelect innovation enables, for the first time, the creation of personalized, microbiome-based probiotics, fitted to any purpose – recovery from illness, chronic condition, or as supplements – and fitted to specific microbiome needs of different ethnicities, age, and gender. MyBiotics won and executed a Phase1 feasibility study in 2015, which served as a basis for its development since and for this project application. MyBiotics’ objectives in this project are to complete the development of the MBSelect technology, develop its first three probiotic products, scale them to industrial level, test them, and produce the 1st batch for initial commercial market testing immediately following the project; followed by full EU & US commercialization and scaling. The success of MBSelect is key in realizing the potential of MyBiotics and enabling the company to grow.
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-EIC-SMEInst-2018-2020-3
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
7414001 Ness Ziona
Israel
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.